605116 logo

Aurisco Pharmaceutical Co.,Ltd. Stock Price

SHSE:605116 Community·CN¥10.0b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

605116 Share Price Performance

CN¥0
-19.85 (-100.00%)
CN¥0
-19.85 (-100.00%)
Price CN¥0

605116 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Solid track record with excellent balance sheet.

1 Risk
3 Rewards

Aurisco Pharmaceutical Co.,Ltd. Key Details

CN¥1.6b

Revenue

CN¥660.1m

Cost of Revenue

CN¥964.4m

Gross Profit

CN¥539.8m

Other Expenses

CN¥424.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 17, 2026
1.05
59.36%
26.13%
37.7%
View Full Analysis

About 605116

Founded
1998
Employees
1784
CEO
Dingjun Chu
WebsiteView website
www.aurisco.com

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

Recent 605116 News & Updates

Recent updates

No updates